Influence of the antiparkinsonian drugs on the plasma level of neuroleptics. 1977

J Gautier, and A Jus, and A Villeneuve, and K Jus, and P Pires, and R Villeneuve

The interaction between various neuroleptics and antiparkinsonian drugs was analyzed by measuring the neuroleptic plasma level before and after withdrawal of antiparkinsonian drugs. The population completing the study consisted of 32 chronic schizophrenics treated with chlorpromazine (8), levomepromazine (14), thioridazine (6), or haloperidol (4). Twenty-five were also receiving benztropine; 4, trihexyphenidyl; and 3, procyclidine. During the first 4 weeks patients remained on neuroleptics and antiparkinsonians, the latter being withdrawn during the 5th week, and the neuroleptics alone being administered during 16 following weeks. The plasma level of neuroleptics was assayed by gas liquid chromatography, once weekly in the morning at two different times. The analysis of variance showed a significant difference in neuroleptic plasma level when patients took neuroleptics only versus the period they had received neuroleptics and antiparkinsonians. The multiple comparison based on Studentized range Q0-05 revealed a significant progressive increase of neuroleptic plasma level during 12 weeks after withdrawal of antiparkinsonian drugs after which a plateau was reached. The hypothetical mechanisms of action of antiparkinsonians on neuroleptic plasma level are discussed.

UI MeSH Term Description Entries
D008297 Male Males
D008728 Methotrimeprazine A phenothiazine with pharmacological activity similar to that of both CHLORPROMAZINE and PROMETHAZINE. It has the histamine-antagonist properties of the antihistamines together with CENTRAL NERVOUS SYSTEM effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) Levomeprazin,Levomepromazine,Levopromazine,Tisercin,Tizercine,Tizertsin
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002746 Chlorpromazine The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. Aminazine,Chlorazine,Chlordelazine,Chlorpromazine Hydrochloride,Contomin,Fenactil,Largactil,Propaphenin,Thorazine,Hydrochloride, Chlorpromazine
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006220 Haloperidol A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) Haldol
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000978 Antiparkinson Agents Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. Antiparkinson Drugs,Antiparkinsonian Agents,Antiparkinsonians,Agents, Antiparkinson,Agents, Antiparkinsonian,Drugs, Antiparkinson

Related Publications

J Gautier, and A Jus, and A Villeneuve, and K Jus, and P Pires, and R Villeneuve
November 1975, The American journal of psychiatry,
J Gautier, and A Jus, and A Villeneuve, and K Jus, and P Pires, and R Villeneuve
June 1976, Biological psychiatry,
J Gautier, and A Jus, and A Villeneuve, and K Jus, and P Pires, and R Villeneuve
October 1981, The American journal of psychiatry,
J Gautier, and A Jus, and A Villeneuve, and K Jus, and P Pires, and R Villeneuve
February 1982, The British journal of psychiatry : the journal of mental science,
J Gautier, and A Jus, and A Villeneuve, and K Jus, and P Pires, and R Villeneuve
January 1987, European journal of clinical pharmacology,
J Gautier, and A Jus, and A Villeneuve, and K Jus, and P Pires, and R Villeneuve
March 1989, La Revue du praticien,
J Gautier, and A Jus, and A Villeneuve, and K Jus, and P Pires, and R Villeneuve
January 1976, British medical journal,
J Gautier, and A Jus, and A Villeneuve, and K Jus, and P Pires, and R Villeneuve
February 1973, Experientia,
J Gautier, and A Jus, and A Villeneuve, and K Jus, and P Pires, and R Villeneuve
December 1964, La Revue du praticien,
J Gautier, and A Jus, and A Villeneuve, and K Jus, and P Pires, and R Villeneuve
February 1981, Annals of emergency medicine,
Copied contents to your clipboard!